文献速递冠心病

多基因风险评分在临床环境中可提升心血管疾病风险预测

Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting.
PubMed 文献 · Eur Heart J · 2024-01-01

GENVASC研究嵌套于英国NHS健康检查项目,纳入44,141名40-74岁无已知CVD个体,采用嵌套病例对照设计比较QRISK2联合CVD-PRS(整合风险工具)与单用QRISK2识别高危个体的效能。结果显示联合策略将后续发生主要CVD事件的高危识别率从61.5%提升至68.7%,在40-54岁人群中提升更明显。

要点

  • QRISK2联合CVD-PRS较单用QRISK2将高危识别率从61.5%提高至68.7%。
  • 40-54岁人群联合策略识别率从26.0%升至38.4%,相对提升47.7%。
  • 联合策略在男女及非白人族裔中均显示额外识别获益。

核心结论

  • 在临床环境中,将遗传信息加入临床风险评估可显著改善对后续发生主要CVD事件个体的高危识别,尤其在年轻人群中。

研究设计与样本

  • GENVASC研究嵌套于英国NHS健康检查项目,2012-2020年纳入147家全科诊所的44,141名40-74岁无已知CVD个体。
  • 采用嵌套病例对照遗传学研究,195例发生主要CVD事件者为病例,396例倾向匹配对照。

主要发现

  • QRISK2识别61.5%(95%CI 54.3%-68.4%)后续发生主要CVD事件者为高危,QRISK2联合IRT识别68.7%(95%CI 61.7%-75.2%),相对增加11.7%(P=1×10^-4)。
  • 病例组较对照组被上调风险等级的OR为2.41(95%CI 1.03-5.64,P=.031)。
  • 40-54岁人群中QRISK2识别26.0%(95%CI 16.5%-37.6%),联合IRT识别38.4%(95%CI 27.2%-50.5%),相对增加47.7%(P=.001)。
  • 联合策略在女性与男性、非白人与白人之间的额外识别比例相似;将CVD-PRS加入ASCVD-PCE或SCORE2评分时结果相似。

关键数值与推荐

  • 高危定义为QRISK2 10年CVD风险≥10%。
  • 主要CVD事件包括CVD死亡、心肌梗死或急性冠脉综合征、冠状动脉血运重建、卒中。

临床怎么用

  • 在NHS健康检查等临床场景中,可考虑将CVD-PRS整合入QRISK2等临床风险评分以提升高危个体识别。
  • 对40-54岁人群,联合评估可能带来更大的额外识别获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A cardiovascular disease polygenic risk score (CVD-PRS) can stratify individuals into different categories of cardiovascular risk, but whether the addition of a CVD-PRS to clinical risk scores improves the identification of individuals at increased risk in a real-world clinical setting is unknown. METHODS: The Genetics and the Vascular Health Check Study (GENVASC) was embedded within the UK National Health Service Health Check (NHSHC) programme which invites individuals between 40-74 years of age without known CVD to attend an assessment in a UK general practice where CVD risk factors are measured and a CVD risk score (QRISK2) is calculated. Between 2012-2020, 44,141 individuals (55.7% females, 15.8% non-white) who attended an NHSHC in 147 participating practices across two counties in England were recruited and followed. When 195 individuals (cases) had suffered a major CVD event (CVD death, myocardial infarction or acute coronary syndrome, coronary revascularisation, stroke), 396 propensity-matched controls with a similar risk profile were identified, and a nested case-control genetic study undertaken to see if the addition of a CVD-PRS to QRISK2 in the form of an integrated risk tool (IRT) combined with QRISK2 would have identified more individuals at the time of their NHSHC as at high risk (QRISK2 10-year CVD risk of ≥10%), compared with QRISK2 alone. RESULTS: The distribution of the standardised CVD-PRS was significantly different in cases compared with controls (cases mean score .32; controls, -.18, P = 8.28×10-9). QRISK2 identified 61.5% (95% confidence interval [CI]: 54.3%-68.4%) of individuals who subsequently developed a major CVD event as being at high risk at their NHSHC, while the combination of QRISK2 and IRT identified 68.7% (95% CI: 61.7%-75.2%), a relative increase of 11.7% (P = 1×10-4). The odds ratio (OR) of being up-classified was 2.41 (95% CI: 1.03-5.64, P = .031) for cases compared with controls. In individuals aged 40-54 years, QRISK2 identified 26.0% (95% CI: 16.5%-37.6%) of those who developed a major CVD event, while the combination of QRISK2 and IRT identified 38.4% (95% CI: 27.2%-50.5%), indicating a stronger relative increase of 47.7% in the younger age group (P = .001). The combination of QRISK2 and IRT increased the proportion of additional cases identified similarly in women as in men, and in non-white ethnicities compared with white ethnicity. The findings were similar when the CVD-PRS was added to the atherosclerotic cardiovascular disease pooled cohort equations (ASCVD-PCE) or SCORE2 clinical scores. CONCLUSIONS: In a clinical setting, the addition of genetic information to clinical risk assessment significantly improved the identification of individuals who went on to have a major CVD event as being at high risk, especially among younger individuals. The findings provide important real-world evidence of the potential value of implementing a CVD-PRS into health systems.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Samani, Beeston, Greengrass, et al. Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting. Eur Heart J. 2024. PMID: 38848106. doi:10.1093/eurheartj/ehae342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。